{"id":388714,"date":"2020-11-25T16:18:31","date_gmt":"2020-11-25T21:18:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388714"},"modified":"2020-11-25T16:18:31","modified_gmt":"2020-11-25T21:18:31","slug":"novavax-to-participate-in-upcoming-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/","title":{"rendered":"Novavax to Participate in Upcoming Conferences"},"content":{"rendered":"
\n

GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax\u2019 COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Piper Sandler 32<\/strong>
\n
\n nd<\/strong>
\n <\/sup>
\n Annual Virtual Healthcare <\/strong>
\n Conference<\/strong>\n <\/td>\n<\/tr>\n
\n Panel<\/em>
\n
Date:<\/td>\n		\n
Tuesday, December 1, 2020<\/td>\n<\/tr>\n
Time:<\/td>\n10:00 a.m. Eastern Time (ET)<\/td>\n<\/tr>\n
Panel title:<\/td>\nThe Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to Be Answered into 2021<\/td>\n<\/tr>\n
Moderators:<\/td>\nEdward A. Tenthoff and Yasmeen Rahimi, Ph.D.<\/td>\n<\/tr>\n
NVAX Panelist:<\/td>\nGregory M. Glenn, M.D., President of Research and Development, Novavax
Additional panelists: Moderna, Inc., Arcturus Therapeutics Holdings, Inc. and Altimmune, Inc.
This event is open to Piper Sandler clients<\/em><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Conference<\/em>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Event:
Participants:<\/td>\n		Fireside chat
Stanley C. Erck, President and Chief Executive Officer, and Dr. Glenn<\/td>\n<\/tr>\n
Webcast:<\/td>\nA replay of the recorded fireside session is available through the events<\/a> page of the Company\u2019s website at ir.novavax.com for 90 days.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Event:
Date:<\/p>\n<\/td>\n		Investor meetings
Wednesday, December 2, 2020<\/td>\n<\/tr>\n
\n Evercore ISI 3<\/strong>
\n
\n rd<\/strong>
\n <\/sup>
\n Annual HealthCONx Conference<\/strong>\n <\/td>\n<\/tr>\n
Date:<\/td>\nThursday, December 3, 2020<\/td>\n<\/tr>\n
Time:<\/td>\n2:15 p.m. Eastern Time (ET)<\/td>\n<\/tr>\n
Participation:<\/td>\nFireside chat and investor meetings<\/td>\n<\/tr>\n
Live webcast:<\/td>\n\n www.novavax.com<\/a>, \u201cInvestors\u201d\/ \u201cEvents\u201d<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About NVX-CoV2373<\/strong>\n <\/p>\n

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax\u2019 recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax\u2019 patented saponin-based Matrix-M\u2122 adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In the Phase 1 portion of its Phase 1\/2 clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a Phase 3 trial in the U.K. and two ongoing Phase 2 studies that began in August; a Phase 2b trial in South Africa, and a Phase 1\/2 continuation in the U.S. and Australia. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $399 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and almost $1.7 billion from the U.S. government.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

\n About Novavax <\/strong>\n <\/p>\n

Novavax, Inc.\u202f(Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.\u202f Novavax\u202fis currently conducting multiple clinical trials for NVX-CoV2373, its vaccine candidate against the virus that causes COVID-19, including a pivotal Phase 3 clinical trial in the United Kingdom to evaluate the efficacy, safety and immunogenicity in individuals aged 18-84 years of age. NanoFlu\u2122, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both candidate vaccines incorporate Novavax\u2019 proprietary saponin-based Matrix-M\u2122 adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.\u202fNovavax\u202fis a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.<\/p>\n

For more information, visit www.novavax.com and connect with us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\n Contacts: <\/strong>\n <\/p>\n

Investors
Erika Trahan
ir@novavax.com<\/a>
240-268-2022<\/p>\n

Media
Brandzone\/KOGS Communication
Edna Kaplan
kaplan@kogspr.com<\/a>
617-974-8659<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax\u2019 COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference. Piper Sandler 32 nd Annual Virtual Healthcare Conference Panel Date: Tuesday, December 1, 2020 Time: 10:00 a.m. Eastern Time (ET) Panel title: The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to Be Answered into 2021 Moderators: Edward A. Tenthoff and Yasmeen Rahimi, Ph.D. NVAX Panelist: Gregory M. Glenn, M.D., President of Research and Development, NovavaxAdditional panelists: Moderna, Inc., Arcturus Therapeutics Holdings, Inc. and Altimmune, Inc. This event is … <\/p>\n

Continue reading “Novavax to Participate in Upcoming Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388714","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNovavax to Participate in Upcoming Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novavax to Participate in Upcoming Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax\u2019 COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference. Piper Sandler 32 nd Annual Virtual Healthcare Conference Panel Date: Tuesday, December 1, 2020 Time: 10:00 a.m. Eastern Time (ET) Panel title: The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to Be Answered into 2021 Moderators: Edward A. Tenthoff and Yasmeen Rahimi, Ph.D. NVAX Panelist: Gregory M. Glenn, M.D., President of Research and Development, NovavaxAdditional panelists: Moderna, Inc., Arcturus Therapeutics Holdings, Inc. and Altimmune, Inc. This event is … Continue reading "Novavax to Participate in Upcoming Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-25T21:18:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Novavax to Participate in Upcoming Conferences\",\"datePublished\":\"2020-11-25T21:18:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/\"},\"wordCount\":579,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/\",\"name\":\"Novavax to Participate in Upcoming Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM=\",\"datePublished\":\"2020-11-25T21:18:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novavax to Participate in Upcoming Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novavax to Participate in Upcoming Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Novavax to Participate in Upcoming Conferences - Market Newsdesk","og_description":"GAITHERSBURG, Md., Nov. 25, 2020 (GLOBE NEWSWIRE) — Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax\u2019 COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference. Piper Sandler 32 nd Annual Virtual Healthcare Conference Panel Date: Tuesday, December 1, 2020 Time: 10:00 a.m. Eastern Time (ET) Panel title: The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to Be Answered into 2021 Moderators: Edward A. Tenthoff and Yasmeen Rahimi, Ph.D. NVAX Panelist: Gregory M. Glenn, M.D., President of Research and Development, NovavaxAdditional panelists: Moderna, Inc., Arcturus Therapeutics Holdings, Inc. and Altimmune, Inc. This event is … Continue reading \"Novavax to Participate in Upcoming Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-25T21:18:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Novavax to Participate in Upcoming Conferences","datePublished":"2020-11-25T21:18:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/"},"wordCount":579,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/","name":"Novavax to Participate in Upcoming Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM=","datePublished":"2020-11-25T21:18:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MjQyNyMzODQ0NTAyIzIwMTkwMzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Novavax to Participate in Upcoming Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388714"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388714\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}